We analyzed the subtypes of cerebrovascular events in 21 105 patients participating in Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 ( ENGAGE AF-TIMI 48 ) comparing outcomes among patients randomized to warfarin versus 2 edoxaban regimens ( high dose , low dose ) .